Genelux Corporation is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of oncolytic viral immunotherapies for patients suffering from solid tumor types. Its advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. The Company is focused on Phase II clinical trial of Olvi-Vec in platinum resistant/refractory ovarian cancer (PRROC). Its Virus and Vaccine (Neoantigen)-Enhanced Adoptive Cell Therapy (V2ACT) Immunotherapy is an indication-agnostic personalized anti-cancer therapy designed to safely maximize the number and effect of cancer neoantigen-specific effector T cells within cancer tissues. Its animal health product candidate, V-VET1, is a genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus that is a naturally attenuated isolate.
